

11 September 2008

Dr Carole Longson
Director
Health Technology Evaluation Centre
National Institute for Health and Clinical Excellence
Level 1A, City Tower
Piccadilly Plaza
Manchester
M1 6NA



*Quarry House
Quarry Hill
Leeds
LS2 7UE*

Tel: 0113 254 5000

Dear Carole

Multiple Technology Appraisal – Sutent (Sunitinib) for Renal Cell Carcinoma

I am writing with regard to the Department of Health's position on Pfizer's proposed scheme for Sutent. This scheme means that the first cycle of treatment is free, has already been offered to the NHS at the local level and appears to have been taken up by a number of NHS Trusts.

This proposal appears relatively simple to administer and is consistent with NHS Financial flows. It is fully transparent and we have no objections from a clinical standpoint. Therefore, I can confirm that the Department of Health is content for NICE to incorporate the proposed scheme into its appraisal.

Yours sincerely

██████████

██████████████████

Head of Clinical and Cost Effectiveness,
Medicines, Pharmacy and Industry Group